Ann Lab Med.  2016 Jan;36(1):79-81. 10.3343/alm.2016.36.1.79.

A t(8;9)(p22;p24)/PCM1-JAK2 Translocation in a Patient With Myeloproliferative Neoplasm and Myeloid Sarcoma: First Report in Korea

• Song I
• Lee DH
• Lee JH
• Jang S
• Huh JR
• Seo EJ

• KMID: 2373505
• DOI: http://doi.org/10.3343/alm.2016.36.1.79

Abstract

No abstract available.

MeSH Terms

Adult
Autoantigens/*genetics
Cell Cycle Proteins/*genetics
Chromosomes, Human, Pair 8
Chromosomes, Human, Pair 9
Humans
Janus Kinase 2/*genetics
Male
Myeloproliferative Disorders/complications/*genetics
Sarcoma, Myeloid/complications/*genetics
Translocation, Genetic
Autoantigens
Cell Cycle Proteins
Janus Kinase 2

Figure

• 

  Fig. 1 Lymph node (LN) and bone marrow (BM) immunohistochemistry. (A) Myeloid sarcoma in an inguinal LN showing increased immature cells with less cytoplasms, round nuclei, and distinct prominent nucleoli (Hematoxylin & Eosin [H&E] stain, ×400); (B) Increased immature cells in an inguinal LN positive for myeloperoxidase (×400) and (C) CD117 (×400); (D) Diluted BM aspiration showing normal hematopoietic cells (Wright stain, ×1,000); (E) BM biopsy showing cellularity of nearly 100% (H&E stain, ×400); (F) Megakaryocytes positive for CD61 without proliferation and atypia (×200); (G) BM biopsy showing grade 2 myelofibrosis (on a 0-3 scale), with diffuse and dense reticulin fibers (Reticulin stain, ×400); (H) focal bundles of collagen fibers (Masson Trichrome stain, ×400).

• 

  Fig. 2 The t(8;9)(p22;p24) translocations and PCM1-JAK2 fusion gene. (A) Karyogram of bone marrow showing 46,XY,t(8;9)(p22;p24)[20]; (B) Reverse transcription-PCR product of the PCM1-JAK2 gene from bone marrow; (C) Genetic sequence and schematic representation of the chimeric PCM1-JAK2 gene.

Reference

1. Bain BJ. Should myeloid and lymphoid neoplasms with PCM1-JAK2 and other rearrangements of JAK2 be recognized as specific entities? Br J Haematol. 2014; 166:809–817. PMID: 24913195.

2. Patterer V, Schnittger S, Kern W, Haferlach T, Haferlach C. Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1. Ann Hematol. 2013; 92:759–769. PMID: 23400675.

3. Saba N. A myeloproliferative neoplasm with translocation t(8;9)(p22;p24) involving JAK2 gene. Blood. 2013; 122:861. PMID: 24079014.

4. Bousquet M, Quelen C, De Mas V, Duchayne E, Roquefeuil B, Delsol G, et al. The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene. Oncogene. 2005; 24:7248–7252. PMID: 16091753.

5. Reiter A, Walz C, Watmore A, Schoch C, Blau I, Schlegelberger B, et al. The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res. 2005; 65:2662–2667. PMID: 15805263.

6. Schwaab J, Knut M, Haferlach C, Metzgeroth G, Horny HP, Chase A, et al. Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes. Ann Hematol. 2015; 94:233–238. PMID: 25260694.

7. Hoeller S, Walz C, Reiter A, Dirnhofer S, Tzankov A. PCM1-JAK2-fusion: a potential treatment target in myelodysplastic-myeloproliferative and other hemato-lymphoid neoplasms. Expert Opin Ther Targets. 2011; 15:53–62. PMID: 21091042.

8. Pileri SA, Ascani S, Cox MC, Campidelli C, Bacci F, Piccioli M, et al. Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. Leukemia. 2007; 21:340–350. PMID: 17170724.